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Une courte administration d'acide 13-cis rétinoïque chez l'homme en bonne 
santé augmente les taux plasmatiques de triglycérides sans influencer la 
sensibilité à l'insuline 
Les mécanismes responsables de la résistance à l'insuline associée à 
l'hypertriglycéridémie chez l'homme sont mal connus. Il a été proposé que 
l'hypertriglycéridémie n'engendrait une résistance à l'insuline que lorsqu'elle est 
associée à une augmentation du transfert de lipides dans le muscle. Selon' cette 
hypothèse, une hypertriglycéridémie secondaire à la diminution de l'élimination de 
particules riches en triglycérides ne devrait pas engendrer de résistance à l'insuline. 
Afin de vérifier cette hypothèse, nous avons étudié la sensibilité à l'insuline (au 
niveau du corps entier et du tissu adipeux) chez 15 sujets volontaires masculins avant 
et après 5 jours d'un traitement par l'acide 13-cis rétinoïque (1 mg/kg/j), un dérivé 
de la vitamine A qui diminue l'élimination des particules riches en triglycérides. Au 
cours d'un clamp hyperinsulinémique euglycémique à 3 paliers, nous avons mesuré 
le métabolisme global du glucose dépendant de l'insuline ( 6,6 2H2 glucose), 
l'oxydation du glucose (calorimétrie indirecte), la lipolyse (2H5 glycérol) et la 
lipolyse du tissu adipeux sous-cutané (microdialyse). L'acide 13-cis rétinoïque a 
augmenté le taux plasmatique de triglycérides de 0.97 ± 0.15 à 1.30 ± 0.22 mmol/l 
(p < 0.02) mais n'a pas eu d'effet sur le métabolisme global du glucose et la lipolyse. 
Ces observations sont compatibles avec une diminution de l'élimination des 
particules riches en triglycérides induite par l'acide 13-cis rétinoïque. L'inhibition de 
la production endogène du glucose et la diminution du glycérol sous-cutané induites 
par l'insuline n'ont pas été affectées par l'administration d'acide 13-cis rétinoïque. 
Nous concluons que la diminution de l'élimination des particules riches en 
triglycérides induite par 5 jours d'acide 13-cis rétinoïque n'a pas d'influence sur les 
mécanismes antilipolytiques ou sur le métabolisme du glucose dépendant de 
l'insuline. Ces résultats soutiennent le concept que la résistance à l'insuline associée à 
l'hypertriglycéridémie se développe principalement quand la production de 
triglycérides est augmentée. 
Short-Tenn Administration of Isotretinoin Elevates Plasma Triglyceride 
Concentrations Without Affecting Insulin Sensitivity in Healthy Humans 
Delphine Stoll, Christophe Binnert, Vincent Mooser, and Luc Tappy 
The mechanism underlying hypertriglyceridemia-associated insulin resistance in humans remains poorly understood~ lt has 
been proposed that hypertriglyceridemia only produces insulin resistance when associated with an increased lipid delivery to 
muscle. Accordingly, hypertriglyceridemia secondary to a decreased clearance of triglyceride-rich particles should not cause 
insulin resistance. To verify this hypothesis, we assessed whole body and adipose tissue insulin sensitivity in 15 healthy male 
volunteers before and after a 5-day administration of isotretinoin (1 mg/kg/d), a vitamin A derivative that decreases the 
clearance of triglyceride-rich particles. Whole body insulin-mediated glucose disposai (6,6 2H2glucose), glucose oxidation 
(indirect calorimetry), lipolysis (2 H5 glycerol), and subcutaneous adipose lipolysis (microdialysis) were evaluated during a 
3-step hyperinsulinemic euglycemic clamp. lsotretinoin increased plasma triglyceride from 0.97 ± 0.15 to 1.30 ± 0.22 mmol/L 
(P < .02), but did not change whole body insulin-mediated glucose disposai and lipolysis. These observations are consistent 
with an isotretinoin-induced inhibition of very-low-density lipoprotein (VLDL)-triglyceride clearance. The suppression of 
endogenous glucose production and the reduction in subcutaneous adipose glycerol concentrations by insulin remained 
equally unaffected after isotretinoin administration. We conclude that the impaired clearance of triglyceride-rich particles 
secondary to a 5-day isotretinoin administration does not impair insulin-mediated antilipolysis or glucose disposai. The data 
support the concept that hypertriglyceridemia-associated insulin resistance develops primarily when triglyceride production 
is increased. 
© 2004 Elsevier /ne. Ali rights reserved. 
H YPERTRIGLYCERIDEMIA is often associated with in-sulin resistance.1,2 The nature of this relationship in 
humans remains unclear. Severa! observations made in animais 
suggest that an increase in very-low-density lipoprotein 
(VLDL) assembly and secretion by the liver may lead to an 
increase in free fatty acid (FF A) delivery to the exh·ahepatic 
tissues, which may induce insulin resistance.3 High-fructose 
diet increases VLDL production, raises plasma triglycerides 
concentration, and induces insulin resistance in rodents.4-6 Fur-
thermore, recent studies have shown that overexpression of 
muscle and/or liver lipoprotein lipase in rodents causes tissue-
specific insulin resistance.7,8 In addition, we recently reported 
that the inhibitory effects of lipids on whole body glucose 
utilization were increased in athletes during exercise and hy-
perinsulinemia, suggesting that endurance training increases 
muscle lipid uptake during contraction while reducing glucose 
transport and oxidation.9 These observations indicate that tis-
sue-specific uptake of lipids is of importance in the develop-
ment of insulin resistance. 
In contrast, hypertriglyceridemia secondary to reducecl utili-
zation of triglyceride-rich lipoproteins appears to be associated 
with unchanged or increased whole body insulin sensitivity. 
Overexpression of apolipoprotein (apo)C-III, which inhibits 
lipoprotein lipase, recluces the clearance of triglyceride-rich 
particles and does not change or increascs insulin action in 
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mice.1° More recently, it was observed that hypertriglyceride-
mia can be inducecl by overexpressing human apoC-I in 
mi ce, 11 ,1 2 presumably through a decrease in the hepatic clear-
ance of VLDL. These animais were shown to have increased 
whole body insulin sensitivity. Altogether these observations 
suggest that increasecl delivery of VLDL-triglycerides or up-
take ofVLDL-associated lipids by peripheral tissues may be an 
important factor in the regulation of tissue insulin sensitivity. 
Hyperinsulinemia seconclary to insulin resistance may subse-
quently further clevate plasma h·iglyceride concentrations by 
increasing FF A reesterification and VLDL secretion,2 thus gen-
erating a vicious cycle. 
lsotretinoin, a vitamin A derivative used in the treatment of 
acne, elevates plasma triglyceride levels in approximately 1 of 
5 subjects,13-1 5 A reduction in the clearance of VLDL particles 
has been identified as the most likely mechanism underlying 
this adverse effect. It appears secondary to an increase in the 
content of apoC-III in VLDL, which interferes with lipoprotein 
lipase-mediated intravascular lipolysis. 16 Alternatively, an in-
crease in VLDL production was postulated and may result from 
a stimulation of the re-esterification ofFFA in the liver or from 
a stimulation of hepatic de novo lipogenesis.17 Here, we per-
formed a detailed assessment of the effects of a short-tetm 
adminish·ation of isotretinoin on lipid metabolism and insulin 
sensitivity in healthy humans. Our results corroborate that 
isotretinoin clevates plasma triglyceride concentrations through 
a recluction of triglyceride clearance. Moreover, they indicate 
that isotretinoin does not impair insulin sensitivity, a finding 
consistent with the hypothesis that hyperh·iglyceridemia pri-
marily incluces insulin resistance when associated with in-
creased lipicl clclivery to insulin-sensitive tissues. 
MATERIALS AND METHODS 
Subjec/s 
A total of 15 male healthy volunteers were enrolled in this study. 
Each volunteer had previously been treated with isotretinoin on average 
5 years earlier (range, 3 to 10). Seven of them had increased their 
plasma triglyceride concentration by more than 1 mmol/L during this 
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Table 1. Characteristics of Study Participants 
ù Triglyceride After 
Subject Weight Height First Treatment ù Triglyceride During 
No. Age (yr) (kg) (ml BMI (kgim2) Waist/Hip Ratio % Fat (mmol/L) This Study (mmol/L) 
38 59 1.75 19.3 
2 23 72 1.84 21.3 
3 20 73 1.83 21.8 
4 39 84 1.73 28.1 
5 22 87 1.86 25.1 
6 26 68 1.72 23 
7 29 71 1.80 21.9 
8 30 74 1.78 23.4 
9 29 81 1.81 24.7 
10 24 99.5 1.7 34.4 
11 33 86 1.88 24.3 
12 23 75 1.77 23.9 
13 25 77 1.69 26.9 
14 23 93 1.85 27 
15 40 73 1.83 21.8 
treatment and the remaining 8 had had unchanged levels. Ali volunteers 
were in good physical condition, had no persona! history of diabetes, 
alcoholism, renal, or hepatic insufficiency, and had normal liver fonc-
tion tests and plasma triglyceride concentrations. Their characteristics 
are shown in Table 1. Mean age was 28.3 :+:: (SEM) 1.7 years (range, 
20 to 40), body mass index (BMI) 24.5 :+:: 0.9 kg/m2 (range, 19 to 34 ), 
percentage body fat (determined using skinfold thickness measure-
ment18) 22.8% :+:: 1.3% (range, 15% to 30%), fat-free mass 60.1 :+:: 1.8 
kg (range, 46 to 74), and waist-to-hip ratio 0.83 :+:: 0.02 (range, 0.6 to 
0.9). The Ethical Conunittee of the Lausanne University Medical 
School approved the experimental protocol, and evcry subject provided 
an informed written consent. 
General Procedure 
Experiments began in the moming after an ovemight fast. Volunteers 
were requested not to consume caffeine or alcohol containing drinks at 
least 24 hours before the study; furthermore, they were asked not to get 
involved in any strenuous physical activity during the 2 days preceding 
the study. 
Each volunteer took pait to the same protocol twice, once before and 
once after isotretinoin had been taken for 5 days at a dose of 1 mg/kg/d. 
Compliance was asce1tained by assessment of mucocutaneous side 
effects. Upon aiTival in the metabolic laboratory, volunteers had one 
indwelling venons cannula inserted into a vein of their right wrist. The 
right hand was subsequently placed into a thermostabilized box heated 
at 56°C to achieve partial arterialization of venous blood. Blood sam-
ples were periodically collected through this catheter. A second in-
dwelling cannula was inserted into an antecubital vein of the contralat-
eral arm for infusion of glucose and glycerol tracers, insulin, and 
glucose. In addition, 2 microdialysis probes (20,000-d eut-off, 3-cm 
membrane length; CMNMicrodialysis, Stockholm, Sweden) were in-
setted percutaneously into the abdominal subcutaneous adipose tissue, 
one on each side of the navel, after administration of light intradennal 
anesthesia (xylocaine 1 %, 0.1 to 0.2 mL). The probes were connected 
to a microinjection pmnp and continuously perfuscd, one with a sterile 
Ringer solution and the other with a sterile Ringer solution supple-
mented with epinephrine at a concentration of 1 µ,rnol/L. Effluent 
dialysate was collected as 15 to 30-minute fractions. Respiratory ex-
changes were continuously monitored using a ventilated hood. 
A primed continuous infusion of 6,6-2H2 glucose and 2H5 glycerol 
was stmted at 7:30 AM. Two hours after the infusion was initiated, a 
hyperinsulinemic euglycemic clamp was started. Three levels of insulin 
0.8 21.5 0.06 0.5 
0.6 20.1 0.1 -0.01 
0.8 16.4 -0.08 0.24 
0.9 30.6 -0.06 0.38 
0.8 14.7 0.1 0.19 
0.8 16.4 0.08 0.58 
0.8 20.1 0.0 -0.18 
0.8 21.5 -0.18 0.45 
0.8 26.2 3.09 1.57 
0.9 29.4 1.09 1.06 
0.9 21.5 1.49 0.19 
0.9 24 1.22 -0.05 
0.9 29.4 1.36 -0.01 
0.9 27.6 1.4 0.14 
0.9 23 2.65 -0.18 
(0.6, 1.2, and 2.4 pmol/kg/min) were perfüsed. Each level lasted 75 
minutes. The exogenous glucose was labeled with 1.25% 6,6-2H2 
glucose to avoid dilution of the tracer by the glucose infusion. Blood 
samples were collected at 5-minute intervals for monitoring of plasma 
glucose concentrations and at 15 or 30-minute intervals for measure-
ments of plasma hormones, substrate concentrations, and 6,6-2H2 glu-
cose and 2H5-glycerol enrichment. 
Analysis 
Plasma glucose concentration was detennined using a Beckman 
Glucose Analyzer 2 (Beckman Instrnments, Brea, CA). Plasma insulin 
concentration was determined by radioimmunoassay (kit from Linco, 
St Charles, MO). Plasma triglyceride concentration was detennined by 
an enzymatic and colorimettic method (BioMérieux, Marcy-l'Etoile, 
France). Plasma FFA concentration was detennined by an enzymatic 
and colorimetric method (kit Wako, Neuss, Gennany). Isotopie em·ich-
ment of glucose19·22 and glyceroF> was determined by gas chromatog-
raphy-mass spectrome!ly (GC 5890/ MS5971, Hewlett-Packard, Palo 
Alto, CA). VLDL particles were separated from plasma by preparative 
ultracentrifugation (45,000 rpm, 4°C, for 17 hours). Total VLDL-lipids 
were ex!l·acted by a modification ofFolch's method.24 The triglycerides 
fraction of VLDL-lipids was isolated by solid-phase extraction on 
aminopropyl silica columns. Fatty acid methyl esters were obtained 
from transmethylation ofVLDL-triglycerides and the ratio of palmitate 
to linoleate was determined by gas chromatography-mass spectrome-
try. Glycerol concentration in dialysate was determined by an enzy-
matic method using a CMA microdialysis analyzer (CMA, Stockholm, 
Sweden). 
Calculation 
Glucose and glycerol appearance and disappearance were calculated 
from plasma 6,6 2H2 glucose and 2H5-glycerol isotopie em·ichments, 
respectively, using Steele's equations.19.25 To futther evaluate the re-
lationship between triglyceride and insulin sensitivity, the change in 
fasting plasma triglyceride concentrations induced by isott·etinoin was 
calculated as fasting triglyceride(isotrciinoin) - fasting triglycer-
ide(no 1",trctinninJ· Similarly, the changes in insulin sensitivity was 
calculated as glucose rate of disappearance [GRdJ(isotrnlinoin) -
GRd(no 1"'''"'inoinJ at the 2 highest insulin infusion rates. A correlation 
between these 2 parameters was then sought. 
i l'I 
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Table 2. Fasting Hormones and Substrate Concentrations Before 
and After lsotretinoin Administration 
Triglycerides (mmol/L) 
VLDL-triglyceride (mmol/L) 
Free fatty acids (mmol/L) 
Plasma glucose (mmol/L) 
Plasma insulin (pmol/L) 
*P< .02 vday 1. 
Statistics 
Be fore 
Treatment 
(day 1) 
0.97 ± 0.15 
0.60 ± 0.13 
0.47 ± 0.03 
5.6 ± 0.1 
59 ± 6 
After 
Treatment 
lday 6) 
1.30 ± 0.22* 
0.77 ± 0.14 
0.49 ± 0.04 
5.6 ± 0.1 
60 ± 6 
Results are given as the mean :+:: SEM. Means were compared using 
analysis of variance (ANOV A) for repeated measurements and paired 
Student's t test. Simple regression analysis was used to search for a 
cotTelation between changes in plasma triglycerides and changes in 
insulin-mediated glucose disposai. 
RESULTS 
The effects of isotretinoin administration on basal substrate 
and hormone concentrations are shown in Tables J and 2. A 
5-day isotretinoin treatment significantly increased fasting 
plasma triglyceride values (Table 1). The changes in plasma 
triglyceride levels observed 3 to 10 years earlier, when the 
subjects had received isotretinoin as a treatment for acne, are 
also shown for comparison. There was no correlation between 
the changes in plasma triglycerides observed in this study and 
those observed 3 to 10 years previously. 
Lipid Metabolism 
A 5-day administration of isotretinoin increased total plasma 
triglyceride and VLDL-tt·iglyceride on average by 33% (P < 
Day 1 Day6 
Fig 1. Total plasma triglyceride concentration before and alter a 
5-day treatment with isotretinoin. The thicl< line represents the av-
erage values of the 15 volunteers. 
STOLL ET AL 
.02) and 37%, respectively (Fig 1). The ratio of palmitic to 
linoleic acicl in VLDL-triglyceride was the same before (2.1 ± 
0.4) and at'ter (2.2 ± 0.5) isotretinoin administration. Total 
cholesterol ( 4.3 ± 0.3 l' 4.5 ± 0.3 mmol/L) and high-density 
lipoprotein (HDL)-cholesterol (1.0 ± 0.1v0.9 ± 0.1 mmol/L) 
remained unchanged. Fasting plasma FFA were identical after 
isotretinoin and in contrai experiments and were suppressed to 
the same extent at each step of euglycemic insulinemia (Fig 2). 
Similarly, fasting glycerol turnover and its suppression by 
insulin were not affected by isotretinoin administration (Table 
3). Adipose interstitial glycerol concentrations were identical in 
the basal state irrespective of stimulation by epinephrine. Fur-
thern1ore, suppression of adipose interstitial glycerol by insulin, 
both without and with epinephrinc, was identical before and 
after isotretinoin (Fig 3). Lipid oxiclation was progressively 
suppressecl by gradecl doses of insulin, but this effect was not 
affected by isotretinoin (Table 3). 
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Fig 2. Plasma glucose, insulin, and FFA concentrations during a 
3-step hyperinsulinemic clamp before (O) and alter (1111) a 5-day treat-
ment with isotretinoin. 
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Fig 3. Concentration in the dialysate collected from subcutaneous 
periombilical adipose tissue in fasting conditions (0) and during in-
sulin infusion at 0.6, 1.2, and 2.4 nmol/kg/min. (A) Probes were 
infused with plain Ringer solution; (B) probes were infused with 
Ringer containing 10-5 mol/L epinephrine to stimulate lipolysis. 
Black bars represent volunteers before, and open bars alter a 5-day 
treatment with isotretinoin. 
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Glucose Metabo/ism 
Glucose production, utilization, and oxidation in basal and 
insulin-stimulated conditions are shown in Table 4. Before 
isotretinoin administration, ail of these parameters of glucose 
metabolism were stimulated in a dose-dependent fashion by 
insulin. However, there was no difference between the test 
performed at baseline and after a 5-day isotretinoin adminis-
tration. Endogenous glucose production was inhibited at each 
step of hyperinsulinemia. Here again, isotretinoin administra-
tion did not alter the suppressive effect of insulin. 
Re/ationship Between Changes in Fasting Plasma 
Trig/yceride and Insu/in Sensitivity 
Figure 4 shows a plot of changes in insulin sensitivity 
( evaluated as GRd during infusion of 1.2 and 2.4 pmol insulin/ 
min v changes in fasting plasma triglyceride concentrations). 
There was no correlation between these 2 variables. 
DISCUSSION 
A 5-day administration of isotretinoin at a dose of 1 mg/kg/d 
produced an average of 33% increase in fasting triglyceride 
concentration, and an average of37% increase in basal VLDL-
triglyceride concentration in these healthy male volunteers. 
Hypertriglycericlemia eau develop as the result of either an 
increase in hepatic triglyceride synthesis and secretion, or a 
decreased clearance of triglycerides from the circulation. Sev-
eral reports in the literature indicate that isotretinoin reduces 
the clearance of VLDL-triglyceride in animals.26-28 Various 
mechanisms have been shown to be possibly involved in this 
process. In humans, it has been reported that isotretinoin in-
creases the level of VLDL apoCII1 16 and hence inhibits li-
poprotein lipase. In rats, isotretinoin has also been observed to 
decrease lipoprotein lipase activity at a post-transcriptional 
level.28 
In contrast, the effects of isotretinoin on hepatic triglyceride 
synthesis have not been clocumented in humans. Stimulation by 
isotretinoin of triglyceride secretion would imply either an 
increased hepatic fatty acid re-esterification or a stimulation of 
hepatic cle nova Jipogenesis. Our results indicate that neither of 
these processes was acutely stimulated after isotretinoin. First, 
isotretinoin did not increase basal plasma FF A concentration or 
whole body glyccrol turnover, nor basal subcutaneous adipose 
tissue glycerol concentration. In order to assess adipose tissue 
lipolysis more sensitively, we also measured epinephrine-stim-
ulated lipolysis in subcutaneous adipose tissue. This was 
equally unaffected by isotretinoin. Furthermore, suppression of 
plasma FFA, interstitial adipose tissue glycerol (with or without 
Table 3. Lipid Metabolism Before and After lsotretinoin Administration 
Before lsotretinoin lday 1) Alter lsotretinoin lday 6) 
lnsulin Infusion lprnol/kg/min) lnsulin Infusion lpmol/kg/minl 
Fasting 0.6 1.2 2.4 Fasting 0.6 1.2 2.4 
Glycerol turnover 
(µmol/kg/min) 2.74 ± 0.91 1.56±0.15 1.53 ± 0.20 1.18 ± 0.18 2.49 ± 0.19 1.64 ± 0.12 1.46±0.13 1.25 ± 0.11 
Net lipid oxidation 
(mg/kg/min) 0.9 ± 0.1 0.8 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.5 ± 0.1 
1 
1 1 
1 1 
1 1 1 
1 1 ·1.·. ' 
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Table 4. Glucose Metabolism Before and Alter lsotretinoin Administration 
Before lsotretinoin lday 1) Alter lsotretinoin lday 6) 
lnsulin infusion lprnol/kg/min) lnsulin Infusion lpmol/kg/min) 
Fasting 0.6 1.2 
Total glucose disposai 
(µmol/kg/min) 11.8 ± 0.6 12.8 ± 0.6 14.1 ± 0.6 
Endogenous glucose production 
(µmol/kg/min) 11.8 ± 0.6 7.3 ± 1.0 4.6 ± 0.8 
Net glucose oxidation 
(µmol/kg/min) 12.9 ± 0.8 12.9 ± 0.5 16.3 ± 0.8 
stimulation by epinephrine), and whole body glycerol turnover 
by graded doses of insulin were not modified by isotretinoin. 
This strongly argues against an enhanced adipose tissue lipol-
ysis. In addition, whole body lipid oxidation and its suppression 
by a graded dose of insulin were not altered by isotretinoin. 
This observation speaks against the hypothesis that isotretinoin 
increased hepatic FFA re-esterification since it would imply an 
alteration of the ratio of lipolysis to fat oxidation. lt remains 
possible that isotretinoin altered hepatic lipid oxidation specit~ 
ically, but that this effect was not detected by whole body 
5 A 
2.5 
0 
1.2 nmol/kg/min 
insulin 
-2.5 
-5 
-7.5-1-----------~ 
-0.5 0 0.5 1.5 
10 B 
5 2.4 nmol/kg/min 
insulin 
0 
-5 
-1 o+---r---,---.----, 
-0.5 0 0.5 1.5 
Change in fasting plasma triglyceride 
(mmol/L) 
Fig 4. Changes in insulin sensitivity [GRd measured during infu-
sion of 1.2 (A) and 2.4 (B) nmol/min insulin] plotted v changes in 
fasting plasma triglyceride concentrations induced by isotretinoin. 
There was no significant correlation between these 2 variables. 
2.4 Fasting 0.6 1.2 2.4 
20.5 ± g 0.7 12.2 ± 0.5 12.4 ± 0.4 14.4 ± 0.7 21.4 ± 0.7 
1.4 ± 0.5 12.2 ± 0.5 8.4 ± 0.7 4.5 ± 0.7 1.7 ± 0.6 
16.7 ± 1.0 12.6 :+: 1.0 13.4 ± 0.9 14.1 ± 0.9 17.0 ± 1.1 
indirect calorimetry. Second, an increased hepatic de novo 
lipogenesis would result in an increased ratio ofpalmitic acid to 
linoleic acid, an essential fatty acid, in VLDL-triglyceride.29 
lsotretinoin, however, die\ not alter the ratio of palmitate to 
linoleate. In view of these considerations, our observations 
support the hypothesis that isotretinoin inhibited VLDL-tri-
glyccride clearance. It remains possible that a stimulation of 
VLDL-triglyceride secretion occurred as a result of changes in 
intrahepatic triglyceride sorting, even in the absence of any 
changes in de novo lipogenesis and fatty acid re-esterification. 
Further studies, with a cletailed evaluation of VLDL-triglycer-
ide kinetics, will be required to unambiguously evaluate the 
mechanisms responsible for isotretinoin-induced hypertriglyc-
eridernia. 
Approximately 1 f 5 patients h·eated with isotretinoin devel-
ops a significant hypertriglyceridernia.13- 15 We therefore se-
lected 2 subgroups of patients previously treated with isotreti-
noin; at this first occasion, patients of one group had had 
markecl hypertriglyceridemia whereas the other had not shown 
changes in plasma triglyceride concentration (data shown in 
Table 1 ). We bac! expected that the samc pattern ofresponse to 
isotretinoin would be repeated in the present study and would 
allow us to clearly sort out the effects of isotretinoin per se of 
those related to hypertriglyceridemia. Contra1y to our expecta-
tion, there was no correlation between the increase in plasma 
triglyceride after the first exposure and those observed in this 
study (data shown in Table 1). The reason for this remains 
unclear, but it is likely that some environmental factors 
changed over the 3- to 10-year period that separated the 2 
exposures and accounted for this cliscrepant response. Further 
studies will be required to identify such factors. The increase in 
plasma triglyccride concentration was also much smaller in the 
present study tha11 after the first exposure, possibly due to the 
shorter titne of exposure to isotretinoin. It therefore remains 
possible that a larger increasc in plasma triglyceride concen-
tration may have been reqnired to reduce insulin sensitivity. 
The present study allowed us to sensitively assess the effect 
of isotretinoin on whole body and regional insulin sensitivity. It 
included hyperinsulinemic clamp studies at 3 levels of insu-
linemia. During the first step, low insulin concentrations were 
attainecl and provided insight into the effects of insulin in 
inhibiting adipose tissue lipolysis. The second and third steps 
involved higher insulin concentrations exetting graded effects 
to inhibit hepatic glucose production and stimulate skeletal 
muscle glucose utilization. Similarly, suppression of endoge-
nous glucose production or of adipose tissue lipolysis (indi-
EFFECT OF JSOTRETINOIN ON INSULIN SENSJTIVITY 
rectly assessed from subcutaneous adipose tissue glycerol) was 
identical with or without isotretinoin. Similarly, insulin-medi-
ated whole body glucose utilization and oxiclation were not 
affected by isotretinoin administration. Since one or sevcral of 
these parameters are invariably altered in insulin-resistant 
states,30 our observation strongly argues against isotretinoin-
induced insulin resistance, at least after a 5-day treatment. 
We considered the hypothesis that the magnitude of hyper-
triglyceridemia (a 0.3-mmol/L increment on average) inclucecl 
by isotretinoin was too small to significantly affect insulin 
sensitivity. This hypothesis, however, appears unlikely since a 
large compilation of data obtained in healthy Europeans 
showed a significantly lower insulin sensitivity in indivicluals 
with similarly mild degrees of hyperh·iglycericlemia .. ' 1 This 
observation has recently been confirmed by Moro et al who 
showed in a large cohort of subjects that there is an association 
between plasma h·iglyceride and insulin sensitivity even at 
plasma h'iglyceride levels in the normal range.32 Furtherrnore, 
there was absolutely no changes in insulin-mediated glucose 
utilisation even in the few individuals who showed substantial 
increases in plasma triglyceride concentrations in response to 
isotretinoin. 
We also considered the hypothesis that duration ofhypertri-
glyceridemia in the present study was too short to alter insulin 
sensitivity. However, a recent study reported only a modest 7% 
decrease in insulin-mediated glucose disposa] in patients 
treated for 5 months with this agent.33 ln a previous report, we 
observed features consistent with insulin resistance in patients 
9 
who had developed isotretinoin-induced hypertriglyceridemia 5 
years previously, as well as in their first-degree relatives.34 This 
suggests that interaction between genetic factors and isotreti-
noin may lead to the development of insulin resistance. The 
genes involved in the pathogenesis of insulin resistance in this 
condition and their role in triglyceride metabolism remain to be 
determined. 
Isotretinoin-induced hypertriglyceridemia, therefore, differs 
from familial combined hyperlipidemia or hypertriglyceride-
mia secondary to high-fructose diets, which are both associated 
with insulin resistance. 1·2•6 This nove! observation allows more 
in-depth focus on the mechanisms linking hypertriglyceridemia 
and insulin resistance in these latter conditions. An increased 
secretion of triglycericle-rich particles may leacl to both hyper-
triglyceridemia and insulin resistance, the latter by increasing 
the amount of fat delivered to insulin-sensitive tissue. Alterna-
tively, insulin resistance in extrahepatic tissue may be the 
primary event, and secondarily may lead to hypertriglyceride-
rnia by increasing adipose tissue lipolysis and hepatic fatty acid 
re-esterification. 
In conclusion, the present study emphasizes recent observa-
tions1 1•12 that elevated triglyceride concentrations may occur 
without insulin resistance. These observations are consistent 
with the hypothesis that an increased hepatic triglyceride se-
cretion, together with an increased delivery of triglyceride to 
skeletal muscle or other organs and tissues involved in meta-
bolic conh·o], are required to induce insulin resistance. 
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